At 2016 Summit, Field Tackles AD-Related Dementias One By One
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
6397 RESULTS
Sort By:
A bit less strapped for funding, researchers are considering the next steps for Lewy body, frontotemporal, and vascular dementia.
Researchers confirm that new cases of dementia are on the wane in the United Kingdom, with the greatest benefits among older men.
At a workshop of the Frontotemporal Dementia Treatment Study Group, advocates and regulatory scientists urged leaders from industry and academia to forge a collaborative approach while the field is still young.
Exome sequencing in families with amyotrophic lateral sclerosis and frontotemporal dementia yields variants of a gene that helps recycle cellular waste.
By examining polymorphisms linked to autoimmune diseases, researchers pinned two loci to Alzheimer’s risk. Both may worsen neurofibrillary tangle pathology.
Hoping for better luck in clinical trials than their Alzheimer’s colleagues had in the past decade, FTD researchers are now chasing biomarkers. It’s slim pickings so far, but neurofilament, tau PET, and MRI are showing promise.
Citing “fantastic opportunity,” FDA and EMA call for rigorous science. Agency scientists tell FTD Treatment Study Group: Explore individualized outcomes, and connect biomarkers to meaningful improvement.
Two new papers rekindle acrimonious debate about exactly what “loss-of-function” means when it comes to presenilin mutations in Alzheimer’s pathogenesis.
C9ORF72 repeats create RNA foci and dipeptide aggregates in mice, but antisense oligonucleotides suppress them.
Backtracking of newly synthesized amyloid precursor protein from the Golgi to the ER facilitates APP modification and Aβ production.
Compared with previously published model lines, these animals develop more features of amyotrophic lateral sclerosis and frontotemporal dementia.
On the heels of news that microglia mediate synaptic loss in Alzheimer’s, researchers report they may do the same in a subtype of FTD caused by progranulin deficiency.
It was not easy, but it got done—and the catch looks nothing like prior synthetic or mouse versions of these species.
Search begins for director of £250 million venture.
The gene-editing technology helps validate risk factors of disease and build better disease models.
No filters selected